Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
EXTON, Pa., Feb. 16, 2016 -- Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs, today announced that David Pernock, Chairman and Chief Executive Officer, will present at the RBC Capital Markets 2016 Global Healthcare Conference at 2:35 p.m. ET on Tuesday, February 23 in New York City.
A live audio webcast of Fibrocell’s presentation will be available under the News & Events section of the company’s website at http://ir.fibrocell.com/ and archived for 30 days. Please visit Fibrocell’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
Fibrocell Trademarks
Fibrocell™ and Fibrocell Science® are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.
About Fibrocell
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell’s most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal fold scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin and joint diseases using genetically-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its gene-therapy product candidate for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon will be commencing preclinical development of a gene therapy for the treatment of chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions. For more information, visit www.fibrocell.com.
Investor Relations Contact: John Woolford Westwicke Partners 443.213.0506 [email protected] Media Relations Contact: Michael Parks 484.356.7105 [email protected]
